Showing results (141-150 of 159) with videos related to
Sort By:
Pageof 16
Lancet (London, England)|February 7, 2021
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trialKristian Reich, Kim A Papp, Andrew Blauvelt, et al.Journal of the American Academy of Dermatology|December 7, 2019
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trialsKristian Reich, Christopher E M Griffiths, Kenneth B Gordon, et al.Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summaryBruce Strober, Diamant Thaçi, Howard Sofen, et al.Lancet (London, England)|September 22, 2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trialAkimichi Morita, Bruce Strober, A David Burden, et al.Journal of the American Academy of Dermatology|September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialBruce Strober, Diamant Thaçi, Howard Sofen, et al.Journal of the American Academy of Dermatology|May 22, 2016
Clinical meaningfulness of complete skin clearance in psoriasisBruce Strober, Kim A Papp, Mark Lebwohl, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.Journal of the American Academy of Dermatology|October 9, 2009
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapyAlan Menter, Neil J Korman, Craig A Elmets, et al.Journal of the American Academy of Dermatology|February 17, 2009
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapiesAlan Menter, Neil J Korman, Craig A Elmets, et al.Journal of the American Academy of Dermatology|June 5, 2009
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agentsAlan Menter, Neil J Korman, Craig A Elmets, et al.Pageof 16